A COMPARISON OF THE SAFETY AND EFFICACY OF MIBEFRADIL AND NIFEDIPINE SR IN PATIENTS WITH RENAL-DISEASE AND HYPERTENSION

The antihypertensive efficacy and safety of mibefradil and nifedipine SR were compared in 143 patients with chronic renal failure and mild-t o-moderate hypertension in a multicenter, double-blind, randomized, pa rallel-design study. At treatment week 12, a significantly greater dec rease in sitting diastolic blood pressure (SDBP) was seen with mibefra dil than with nifedipine SR (12.8 mmHg vs 8.1 mmHg, respectively; p = 0.014). A significantly greater number of mibefradil-treated patients achieved normalization of SDBP by week 12 (62% vs 37%; p < 0.01). The changes in renal function parameters and the incidence of adverse even ts were similar in both groups. In this population, 12 weeks of treatm ent with mibefradil were more effective than nifedipine SR for lowerin g blood pressure and had similar effects on renal function parameters.